Selective antisense compounds and uses thereof

1. An oligomeric compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides, wherein the modified oligonucleotide has a modification motif comprising:

a 5′-region consisting of 5-8 linked 5′-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, wherein the 5′-region comprises an AAABB motif, wherein each A is a non-bicyclic modified nucleoside and each B is a bicyclic nucleoside, and wherein the 3′-most 5′-region nucleoside is the second B of AAABB;

a 3′-region consisting of 2-8 linked 3′-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 3′-region nucleoside is a modified nucleoside and wherein the 5′-most 3′-region nucleoside is a modified nucleoside; and

a central region between the 5′-region and the 3′-region consisting of 6-12 linked unmodified deoxynucleosides;

wherein the modified oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of a target region of a nucleic acid associated with a huntingtin transcript, and wherein the nucleobase sequence of the target region of the target nucleic acid differs from the nucleobase sequence of at least one non-target nucleic acid by 1-3 differentiating nucleobases, and wherein the target nucleic acid and the non-target nucleic acid are alleles of the huntingtin gene.

2. The oligomeric compound of claim 1 , wherein the single differentiating nucleobase is a single-nucleotide polymorphism.

3. The oligomeric compound of claim 2 , wherein the single-nucleotide polymorphism is selected from among: rs6446723, rs3856973, rs2285086, rs363092, rs916171, rs6844859, rs7691627, rs4690073, rs2024115, rs11731237, rs362296, rs10015979, rs7659144, rs363096, rs362273, rs16843804, rs362271, rs362275, rs3121419, rs362272, rs3775061, rs34315806, rs363099, rs2298967, rs363088, rs363064, rs363102, rs2798235, rs363080, rs363072, rs363125, rs362303, rs362307, rs362310, rs10488840, rs362325, rs35892913, rs363102, rs363096, rs11731237, rs10015979, rs363080, rs2798235, rs1936032, rs2276881, rs363070, rs35892913, rs12502045, rs6446723, rs7685686, rs3733217, rs6844859, and rs362331.

4. The oligomeric compound of claim 2 , wherein the single-nucleotide polymorphism is selected from among: rs7685686, rs362303, rs362307, rs4690072 and rs363088.

5. The oligomeric compound of claim 4 , wherein the 3′-most bicyclic nucleoside of the 5′-region is selected from among a cEt sugar moiety and an LNA sugar moiety.

6. The oligomeric compound of claim 5 , wherein the central region consists of 6-10 linked nucleosides.

7. The oligomeric compound of claim 6 , wherein the central region consists of 7 linked nucleosides.

8. The oligomeric compound of claim 4 , wherein at least one non-bicyclic modified 5′-region nucleoside comprises a 2′-substituted sugar moiety comprising a 2′ substituent selected from among: halogen, optionally substituted allyl, optionally substituted amino, azido, optionally substituted SH, CN, OCN, CF 3, OCF 3 , O, S, or N(R m )-alkyl; O, S, or N(R m )-alkenyl; O, S or N(R m )-alkynyl; optionally substituted O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally substituted alkaryl, optionally substituted aralkyl, optionally substituted O-alkaryl, optionally substituted O-aralkyl, O(CH 2 ) 2 SCH 3, O—(CH 2 ) 2 -O—N(R m )(R n ) or O—CH 2 -C(═O)—N(R m )(R n ), where each R m and R n is, independently, H, an amino protecting group or substituted or unsubstituted C 1 -C 10 alkyl;

wherein each optionally substituted group is optionally substituted with a substituent group independently selected from among: hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO 2 ), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.

9. The oligomeric compound of claim 4 , wherein at least one non-bicyclic modified 5′-region nucleoside comprises a 2′-substituted sugar moiety comprising a 2′-substituent selected from among: a halogen, OCH 3 , OCH 2 F, OCHF 2 , OCF 3 , OCH 2 CH 3 , O(CH 2 ) 2 F, OCH 2 CHF 2 , OCH 2 CF 3 , OCH 2 -CH═CH 2 , O(CH 2 ) 2 -OCH 3 (MOE), O(CH 2 ) 2 -SCH 3 , O(CH 2 ) 2 -OCF 3 , O(CH 2 ) 3 -N(R 1 )(R 2 ), O(CH 2 ) 2 -ON(R 1 )(R 2 ), O(CH 2 ) 2 -O(CH 2 ) 2 -N(R 1 )(R 2 ), OCH 2 C(═O)—N(R 1 )(R 2 ), OCH 2 C(═O)—N(R 3 )—(CH 2 ) 2 -N(R 1 )(R 2 ), and O(CH 2 ) 2 -N(R 3 )—C(═NR 4 )[N(R 1 )(R 2 )]; wherein R 1 , R 2 , R 3 and R 4 are each, independently, H or C 1 -C 6 alkyl.

10. The oligomeric compound of claim 9 , wherein the 2′-substituent is selected from among: a halogen, OCH 3 , OCF 3 , OCH 2 CH 3 , OCH 2 CF 3 , OCH 2 -CH═CH 2 , O(CH 2 ) 2 -OCH 3 , O(CH 2 ) 2 -O(CH 2 ) 2 -N(CH 3 ) 2 , OCH 2 C(═O)—N(H)CH 3 , OCH 2 C(═O)—N(H)—(CH 2 ) 2 -N(CH 3 ) 2 , and OCH 2 -N(H)—C(═NH)NH 2 .

11. The oligomeric compound of claim 7 , wherein each non-bicyclic modified 5′-region nucleoside of the AAABB motif comprises a 2′-MOE sugar moiety.

12. The oligomeric compound of claim 11 , comprising at least one modified 3′-region nucleoside comprising a bicyclic sugar moiety.

13. The oligomeric compound of claim 12 , comprising at least one modified 3′-region nucleoside comprising a cEt sugar moiety.

14. The oligomeric compound of claim 13 , comprising at least one modified 3′-region nucleoside comprising a 2′-substituted sugar moiety.

15. The oligomeric compound of claim 14 , wherein the 2′-substituent is selected from among: a halogen, OCH 3 , OCF 3 , OCH 2 CH 3 , OCH 2 CF 3 , OCH 2 -CH═CH 2 , O(CH 2 ) 2 -OCH 3 , O(CH 2 ) 2 -O(CH 2 ) 2 -N(CH 3 ) 2 , OCH 2 C(═O)—N(H)CH 3 , OCH 2 C(═O)—N(H)—(CH 2 ) 2 -N(CH 3 ) 2 , and OCH 2 -N(H)—C(═NH)NH 2 .

16. The oligomeric compound of claim 14 , comprising at least one modified 3′-region nucleoside comprising a 2′-MOE sugar moiety.

17. The oligomeric compound of claim 11 , wherein each B of the AAABB motif is a cEt sugar moiety.

18. The oligomeric compound of claim 17 , wherein the 3′-region comprises a BBA motif, wherein each B is a cEt sugar moiety and A is a 2′-MOE sugar moiety.